Basel, October 29, 2024 – Novartis announced today that Scemblix ® (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible for adjuvant treatment ...

Job Title Sort ascending Business Location Site Date Posted Senior Scientist - in-vivo pharmacology/oncology (Radioligand Therapy) (80-100%*) Regular, Full time Pharma Research Switzerland Basel (City ...

Explore opportunities with Novartis below.

At Novartis, we innovate, develop and operate on a vast scale. You can be part of it. Join our creative community of professionals and you will find opportunities to make an unprecedented impact – on ...

This tool allows you to determine the current value and the yield of a given amount of stock invested in the past. Fill in the amount invested or amount of the stock, as well as the purchase date, in ...

Chronic spontaneous urticaria (CSU) is a serious condition that affects approximately 1.7 million people in the United States and is characterized by itchy hives, deep tissue swelling (angioedema), or ...

V Novartisu spodbujamo inovativnost in razvoj ter delujemo na številnih področjih. Tudi vi lahko postanete del tega, del naše zgodbe. Pridružite se naši ustvarjalni skupnosti strokovnjakov in našli ...

Prozkoumejte pracovní příležitosti ve společnosti Novartis v seznamu níže. Pro další pozice ve společnosti Novartis Gene Therapies (dříve AveXis) navštivte GTx Hledání práce. Drug Product Technologies ...

诺华 承 诺 与残障人士共事并 为 他 们 提供合理的便利 设 施。如果您由于健康状况或残障 在招聘 过 程的任何 环 节 需要合理便利 设 施 或者 为 了履行 职 位的基本 职 能 请发 送 电 子 邮 件 ...

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the ...